Introduction
The onset of bipolar disorder (BD) typically occurs during youth and early adulthood, placing women at risk throughout their childbearing years.
Recent psychiatric literature, while containing no clear evidence that pregnancy per se increases the risk of bipolar recurrences, indicates that the postpartum is a high-risk period for recurrences in bipolar patients (Sharma and Pope 2012; Di Florio et al. 2013) . Moreover, our previous study on a large sample of medication-free bipolar women showed a higher incidence of postpartum recurrences in type I disorder (Maina et al. 2014) .
It is known that women who discontinue mood stabilizers before or during pregnancy are particularly at high risk of mood episodes. Viguera and colleagues found that postpartum recurrences after lithium discontinuation in pregnant women with BD were 2.9 times more frequent than recurrences in non-pregnant women (Viguera et al. 2000) .
To date, lithium has substantial evidence that supports the efficacy in the peripartum period (Bergink and Kushner 2014) and the efficacy/safety ratio still seems to be in favor of lithium in respect to other mood stabilizers (Gentile 2012) . Nevertheless, the current available data on the efficacy of lithium in bipolar pregnant women is still limited. Furthermore, data on specific subgroups of women with BD is needed.
The aim of the present study was to evaluate the efficacy of lithium prophylaxis during pregnancy and the postpartum period in a sample of women with lithium-responsive bipolar I disorder (BDI).
Materials and methods

Subjects
The subjects selected for this study were women with BD being treated in the Psychiatric Unit of the Department of Neurosciences (University of Turin) and who wished to become pregnant. The recruitment period was from 2008 to 2013.
The inclusion criteria were minimum 18 years of age, main diagnosis of BDI according to DSM-IV-TR, pregnancy planning, and verbal consent to participate in the study.
The general exclusion criteria are as follow: the presence of any medical illness, current alcohol, and/or substance abuse, being heavy cigarette smoker (≥10 cigarettes/day), and drug treatment with any agent (except lithium) which may interfere with fetal growth.
Procedures
Sociodemographic data and clinical characteristics were obtained through a clinical interview and a review of individual patients' medical records.
All women fulfilling the inclusion criteria underwent preconception counseling that included both a psychiatric and an obstetric evaluation on the risk-benefit ratio of lithium treatment during pregnancy and the postpartum period. They were also informed that breastfeeding was not recommended. All the participants made the decision to continue prophylaxis with lithium following a thorough discussion with their clinicians.
The women started a daily supplementation of 4 mg folic acid beginning 1 month before trying to get pregnant and continuing through the first 3 months of pregnancy (Huhta and Linask 2015) .
From the preconception period until the third month after delivery, all subjects were followed up by psychiatrists (monthly appointments). Where necessary, the plasma levels of lithium were adjusted before pregnancy in order to be within the range of 0.5 and 0.8 Mmol/l. During pregnancy and the postpartum period dosage adjustments were permitted in a flexible manner based on the clinical efficacy for individual patients and the level of lithium in their plasma. As suggested by recent guidelines, lithium was stopped 24 to 48 h before the scheduled cesarean deliveries or at the onset of labor in the event of a spontaneous delivery (Ng et al. 2009 ). Discontinuation of lithium lasted until the day after the childbirth.
Furthermore, all patients received supportive psychotherapy from the first trimester of pregnancy until the third month after childbirth with the primary objective of improving the patient's adaptation to her new life situation. All women underwent preconception counseling, prenatal care, and delivery at a specialized center for high risk pregnancies with a neonatal intensive care unit.
Results
Of the 17 lithium-responsive female patients selected, one of them had two pregnancies, which were both included and followed in the study. The statistical analysis carried out took into account both the number of enrolled patients (n = 17) and the total number of pregnancies (n = 18). None of the included patients had shown severe BD recurrences and/or had been hospitalized for psychiatric disorders in the 24 months before the study.
The sociodemographic and clinical characteristics of the sample women are shown in Table 1 . The sample was characterized by a high number of past episodes (before prophylaxis with lithium) with severe symptomatology. A history of psychotic symptoms emerged in 83.3 % of the subjects, mixed features in 88.9 %, and suicide attempts were reported in 17.6 %. All 17 women had been hospitalized at least once, and nearly 50 % had a history of compulsory treatment. Finally, the four women with previous pregnancies (before prophylaxis with lithium) had experienced severe postpartum mood episodes. The mean daily lithium dose and the lithium plasma levels during pregnancy are shown in Table 2 . Lithium was generally well tolerated: three women became overweight, two women reported mild polyuria and polydipsia (which had already been reported in the lithium treatment before History of past pregnancy loss, n (%) 1 (5.9) pregnancy). Table 2 also shows the pregnancy outcomes. No congenital abnormalities occurred. Three babies with mild hypotonia ('Floppy Infant Syndrome') spontaneously recovered. Psychiatric recurrences during pregnancy were found in two pregnancies (11.2 %) in two different women (11.8%): one mild depressive episode and one hypomanic episode, both were treated by increasing the lithium dosage slightly. Postpartum disorders occurred after five childbirths (27.8%) in five patients (29.4%): two mild depressive episodes, one hypomanic episode with mixed features, and two anxiety disorders NOS. Both postpartum depressive episodes were successfully treated with an increase in the lithium dosage and by intensifying psychotherapy sessions.
The postpartum hypomanic episode was treated with low doses of adjunctive olanzapine (5 mg per day). Such an episode occurred after the first childbirth of the patient with two pregnancies during the study period, while there were no bipolar recurrences after the second childbirth.
Finally, both postpartum anxiety disorders NOS were successfully managed by intensifying psychotherapy sessions and by prescribing benzodiazepines as needed.
Discussion and conclusions
The aim of this prospective observational study was to assess the efficacy of lithium prophylaxis during pregnancy and after childbirth in a specific subpopulation of patients suffering from lithium-responsive BDI.
Our hypothesis was that the continuation of lithium prophylaxis would help such high-risk patients avoid experiencing peripartum bipolar recurrences.
We found that bipolar recurrences of any polarity during pregnancy occurred in 11.1 % of the women. This result is consistent with the findings of Bergink and colleagues (2012) who found a relapse rate of 19.4 % in lithium-treated pregnant women. It should also be emphasized that in our sample the severity of recurrences during the pregnancies was mild and that hospitalization was avoided.
Furthermore, the rate of psychiatric disorders after delivery was 29.4 %. In other studies of unmedicated bipolar women, the postpartum recurrence rate was generally much higher: in a recent study carried out on a group of non-medicated bipolar women during pregnancies, the postpartum recurrence rate was 75 % (Maina et al. 2014) . The finding, nonetheless, is not consistent with several investigations on lithium-treated women during pregnancy that reported lower recurrence rates: in a study of high-risk women with BD who remained stable throughout pregnancy and who used prophylactic treatment with lithium, only 7.7 % relapsed postpartum (Bergink et al. 2012 ). There are two reasons which may explain the higher prevalence (29.4 %) that we found. First, it should be considered that only three patients (17.7 %) showed postpartum mood episodes, while two patients (11.7 %) presented transient anxiety disorders. Moreover, the recurrences observed were mild without any need for hospital admission. Second, our data were derived from a sample with severe BDI, with high rate of previous psychotic symptoms, suicide attempts, and compulsory treatments.
The positive results of this study could be also explained by the effect of the supportive psychotherapy. As stated by Swartz and Frank (2001) , psychosocial therapies are important adjunctive treatments to medication for BD, and they help the woman and her family to understand the disorder, adhere to medication, manage stress, and prevent relapse. Lithium was generally well tolerated, and no serious side effects occurred both to the pregnant women and to the babies. The association between lithium treatment during pregnancy and a higher risk of cardiovascular defects was recently confirmed (Diav-Citrin et al. 2014) . On the other hand, Bodén and colleagues stated that BD in women during pregnancy, whether treated or not, was associated with increased risks of adverse pregnancy outcomes (Bodén et al. 2012) . Our findings can first be explained by the small sample size. Second, all patients underwent a daily supplementation of folic acid from the preconception period. Third, all women were treated with lithium monotherapy (no other drugs were allowed) and the lithium serum levels were kept close to the lower limit of efficacy range.
